The Car T Cell Therapy Market To Re-Ignite With Innovation In The Next Decade

1
Car T Cell Therapy Market
Report Id PMRREP28264 Category Life Science
Healthcare
2
About Persistence Market Research
Customized Research
Persistence Market Research(Persistence Market
Research) is a premier provider of syndicated
research reports, custom research reports, and
consulting services. We deliver a complete
packaged solution, which combines current market
intelligence, statistical anecdotes, technology
inputs, valuable growth insights, aerial view of
the competitive framework, and future market
trends. We provide research services at a global
as well as regional level key regions include
GCC, ASEAN, and BRIC. Our offerings cover a broad
spectrum of industries including Chemicals,
Materials, Energy, Technology, Healthcare, and
Retail. We have a global presence with delivery
centers across India specializing in providing
global research reports and country research
reports. Persistence Market Research is
headquartered out of London, U.K., with a
state-of-the-art delivery center located in Pune,
India. We combine our knowledge and learning from
every corner of the world to distill it to one
thing the perfect solution for our client.
Syndicated Research
Investment Research
Social Media Research
Research Capabilities
Sector Coverage

• Customized Research
• Syndicated Research
• Investment Research
• Social Media Research

• Automotive and Transportation
• Electronics, Semiconductor, and ICT
• Retail and Consumer Products
• Industrial Automation and Equipment

• Chemicals Materials
• Food and Beverages
• Services and Utilities
• Energy, Mining, Oil, and Gas

Subscription Information
For detailed subscription information please
contact Website www.persistencemarketresearch.co
m For sales queries or new topics email us on
sales_at_persistencemarketresearch.com
3
The Car T Cell Therapy Market To Re-Ignite With
Innovation In The Next Decade

• A considerable dip in the development of
  effective chemotherapy agents is expected to
  account for increasing preference for CAR T-cell
  therapy as an effective immunotherapy.
• In cases where patients do not seem responsive to
  these therapies, especially in case of relapsed
  or refractory B-cell lymphoma, CAR T-cell therapy
  has been proven to be highly effective.
• A new research study of Persistence Market
  Research (PMR) suggests that the increase in
  product availability in developed regional
  markets such as North America, Europe, and Japan,
  with high incidence of relapsed cancer will
  accelerate CAR T-cell therapy market in the near
  future.
• CAR T-cell therapy is based on a personalized
  approach and thus, ensures improved patient
  compliance that tends to changing the perception
  towards its adoption. Prominently driven by this,
  global CAR T-cell therapy market is expected to
  reach the revenues worth US 800 Mn by the end of
  2019 and would exhibit spectacular growth through
  2026, at an estimated CAGR of 18.

Get Sample Copy of Report _at_ https//www.persistenc
emarketresearch.com/samples/28264 
4
Strategic Expansion by Dominant Players
Benefiting Market
CAR T-cell therapy market is expected to witness
significant growth, majorly attributed to new
product launches that are lined up in the near
future and multiple developments in CAR T-cell
therapy targeting other cancer types. North
America and Europe are expected to hold a major
share in global CAR T-cell therapy market, with
active production sites only in the U.S.
Manufacturers thus need to send across sample of
T-cells from Europe to the U.S. and then return
final products to Europe post manufacturing. This
process would increase the overall production
costs, average treatment waiting time for
patients, and ultimately limits the potential CAR
T-cell therapy market growth. To overcome such
challenges, Novartis AG and Gilead Sciences Inc.,
dominant companies in the CAR T-cell therapy
market, are strategizing on expansion to meet the
growing CAR T-cell therapy demand in other
regions. Novartis AG, a manufacturer of CAR
T-cell therapy product Kymriah is expanding its
production facility with investment of over US
91.5 million through 2021 in Stein, Switzerland.
Similarly, Gilead Sciences Inc. manufacturer of
Yescarta, is focusing on expanding production
facility in the Netherlands, with operations
expected to commence by end of 2020.
Access Full Report _at_ https//www.persistencemarket
research.com/checkout/28264
5
(No Transcript)